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Abstract
Background
The aim of this study was to evaluate whether soluble frizzled-related protein 4 (sFRP4)
concentration in the first trimester of pregnancy is individually, or in combination with Leptin,
Chemerin and/or Adiponectin, associated with the development of gestational diabetes
(GDM).
Methods
In a nested case-control study, 50 women with GDM who spontaneously conceived and
delivered a live-born infant were matched with a total of 100 uncomplicated singleton control
pregnancies based on body mass index (± 2 kg/m2), gestational age at sampling (exact day)
and maternal age (± 2 years). In serum samples, obtained between 70–90 days gestational
age, sFRP4, Chemerin, Leptin and Adiponectin concentrations were determined by ELISA.
Statistical comparisons were performed using univariate and multi-variate logistic regres-
sion analysis after logarithmic transformation of the concentrations. Discrimination of the
models was assessed by the area under the curve (AUC).
Results
First trimester sFRP4 concentrations were significantly increased in GDM cases (2.04 vs
1.93 ng/ml; p<0.05), just as Chemerin (3.19 vs 3.15 ng/ml; p<0.05) and Leptin (1.44 vs 1.32
ng/ml; p<0.01). Adiponectin concentrations were significantly decreased (2.83 vs 2.94 ng/
ml; p<0.01) in GDM cases. Further analysis only showed a weak, though significant, correla-
tion of sFRP4 with Chemerin (R2 = 0.124; p<0.001) and Leptin (R2 = 0.145; p<0.001), and
Chemerin with Leptin (R2 = 0.282; p<0.001) in the control group. In a multivariate logistic
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regression model of these four markers, only Adiponectin showed to be significantly associ-
ated with GDM (odds ratio 0.12, 95%CI 0.02–0.68). The AUC of this model was 0.699 (95%
CI 0.605–0.793).
Conclusion
In the first trimester of pregnancy, a multi-marker model with sFRP4, Leptin, Chemerin and
Adiponectin is associated with the development of GDM. Therefore, this panel seems to be
an interesting candidate to further evaluate for prediction of GDM in a prospective study.
Introduction
Gestational diabetes mellitus (GDM) is defined as glucose intolerance that is first identified
during pregnancy and, in the majority of cases, resolves after delivery. GDM is a major health
problem affecting up to 10% of all pregnancies and its incidence is increasing [1]. GDM is
known to be associated with a higher risk of macrosomia at birth, but also with serious long-
term complications for mothers and their infants, reflecting in a significant higher risk of met-
abolic, including Diabetes Mellitus Type 2 (T2DM), and cardiovascular disease in later life [2–
5].
However, accumulating evidence suggests that GDM is different from T2DM and that it is
characterized by a mix of several pathologies with more than one potential cause, ranging
from a hormonal to an autoimmune origin [6–12]. This suggests that prediction of GDM,
prior to its onset, should be based on multiple markers rather than a single marker.
Screening for GDM in the first trimester of pregnancy allows prevention and intervention
opportunities [13–16] and may, therefore, limit the risks of related adverse pregnancy outcome
and subsequent health issues of mother and child later in life [17–22]. Currently, there are first
trimester prediction models for GDM available and these are mainly based on demographic
parameters [23]. However, the addition of biochemical markers might improve the perfor-
mance of these prediction models [24,25]. A reason for this might be that biochemical markers
are more related to the direct pathophysiology and several potential prognostic and diagnostic
markers for the first and second trimester have already been described [5,26–34]. Although,
none of these markers has been developed into a clinical test so far.
Adipokine markers such as Adiponectin, Chemerin and Leptin have previously been inves-
tigated in people with diabetes mellitus (DM) as well as women with GDM [35,36]. In women
with GDM, Adiponectin blood concentrations are significantly decreased and this decrease is
already detectable during the first trimester. For that reason, Adiponectin has been suggested
as a predictive biomarker for the development of GDM [37,38]. Adiponectin is an adipocyto-
kine abundantly present in the circulation and involved in regulating glucose concentrations
as well as fatty acid breakdown [39,40]. Moreover, higher Chemerin and Leptin concentrations
during early pregnancy have also been shown to be associated with the development of GDM
suggesting that these two adipocytokines can also be used as predictive biomarkers of GDM
[32,41]. Chemerin modulates adipogenesis and immune system functions by binding to its
own receptor [42–44]. Leptin is the primary negative feedback signal from stored energy on
energy intake [45]. During pregnancy elevated Leptin concentrations lead to reduced food
intake [46].
Secreted Frizzled-Related Proteins modulate Wnt signalling through antagonizing the
molecular pathway by a direct interaction with Wnt and they have a role in regulating cell
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growth, differentiation of several cell types and metabolic processes [47–49]. In mammals, this
family comprises five members that are all potent inhibitors, but their other possible biological
functions are less clear [50]. One of these members, Secreted Frizzled-Related Protein 4
(sFRP4), has been shown to play a role in the regulation of glucose resistance by controlling
insulin secretion from islet cells [51]. With respect to this glucose resistance, sFRP4 is
increased during GDM in the second trimester (i.e.�14 weeks) [52,53]. Interestingly,
increased serum concentrations of sFRP4 were observed years before the diagnosis of T2DM.
This strongly suggests that this protein might also be of clinical value in the first trimester for
the early prediction of GDM [51,54,55]. Therefore, first trimester sFRP4 concentrations were
assessed in this study to investigate the potential role of sFRP4 as an individual biomarker, as
well as in combination with Chemerin, Leptin and/or Adiponectin in the development of
GDM.
Methods
Subjects
The samples in this study were derived from a large cohort of women participating in the rou-
tine Dutch first-trimester Down syndrome screening between 2011 and 2012. As part of this
screening, maternal age, gestational age (GA) at sampling, maternal weight and body mass
index (BMI), method of conception, pre-existent diabetes, and smoking status were recorded
by a midwife or gynaecologist. For all women, a serum sample was collected and subsequently
stored at -20˚C. GA was based on the fetal crown-rump length (CRL) measured during first
trimester ultrasound examination using the formula of Robinson and Fleming [56]. Informa-
tion about pregnancy outcomes, including pre-eclampsia and GDM, were self-reported by the
participating women after delivery. All (demographic) data and anonymized samples were
selected and supplied to us by the Dutch National Institute of Public Health and Environment.
We did not have access to the patient records and patients actively contributed to after written
informed consent. Since samples were processed anonymously without any feedback to partic-
ipants, medical ethical committee approval was not necessary.
For this nested case-control study, we selected 50 serum samples drawn between 70–90
days GA from women with GDM who had no pre-existing type I or type II diabetes, who con-
ceived spontaneously, who delivered a singleton live-born infant between 36- and 42-weeks
GA, and who provided written consent for the use of spare serum for research purposes. To
study crude associations and avoid potential confounding, each case was matched with two
control samples from women with an uncomplicated pregnancy. Matching was based on GA
(exact day), maternal age (± 2 years) and BMI (± 2 kg/m2).
According to standard Dutch guidelines, GDM was diagnosed based on a 75-gram oral glu-
cose tolerance test (OGTT) when one or two of the following thresholds were exceeded: fasting
glucose� 7.0 mmol/L, 2 h glucose� 7.8 mmol/L. An OGTT was only performed when indi-
cated (e.g. history of GDM in an earlier pregnancy, DM in first degree relatives, development
of any GDM symptoms such as excessive fetal growth on ultrasound etc.). Birth weight was
adjusted for gestational age, sex and parity and converted to percentiles according to Dutch
growth charts [15].
Adipokine analysis
Adiponectin (DY1065, R&D systems, Minneapolis, MN, USA), Chemerin (DT2324, R&D sys-
tems, Minneapolis, MN, USA) and Leptin (DY398, R&D systems, Minneapolis, MN, USA)
were analysed in serum using commercially available enzyme linked immunosorbent assay
(ELISA) kits according to the manufacturers’ instructions. Samples were diluted 1:5000 for
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Adiponectin, 1:500 for Chemerin and 1:250 for Leptin. When the concentration at the initial
dilution was found to exceed the highest standard concentration, the sample was tested again
in a tenfold higher dilution. The inter-assay and intra-assay variation were below 10% for all
three assays.
The concentration of sFRP4 was also determined by ELISA (SEF878Hu, Cloud-Clone
Corp., Houston, TX, USA) according to the manufacturer’s instructions for use. Samples were
diluted 1:50 and when the concentration at the initial dilution was found to exceed the highest
standard concentration, the sample was tested again in a tenfold higher dilution. The inter-
assay and intra-assay variation were 12% and 10%, respectively.
All serum samples were tested in triplicate, coded and evaluated by the investigator, who
was blinded for the fact whether the sample was from an individual with a healthy pregnancy
or one who developed GDM during her pregnancy.
Statistical analysis
Baseline characteristics were expressed as median and interquartile range for continuous vari-
ables and categorical variables were expressed as numbers and percentages. Logarithmic trans-
formation was applied for all markers to obtain normal distributions. Statistical comparisons
between cases and controls were performed using Mann-Whitney U or Chi-square tests.
Univariate and multivariate logistic regression analysis was used to study the association
between the marker concentrations and GDM. The discrimination of the individual marker
and the multivariate model were compared by the area under the curve (AUC) of the receiver-
operating curve (ROC). Additionally, correlation between the markers within the groups were
assed using scatter plots and Pearson correlation coefficients. All statistical analyses were per-
formed using SPSS (IBM version 26, Armonk, NY, USA) and p-values <0.05 were considered
statistically significant.
Results
In some cases, serum samples had to be excluded after ELISA analysis, because protein con-
centrations were below the lower limit of detection of the standard curve. The baseline charac-
teristics of all cases and controls are shown in Table 1, revealing no significant differences in
maternal age, maternal weight, maternal BMI, parity, and gestational age at sampling. Also, no
significant differences were found in pregnancy outcomes, such as gestational age at delivery
and birth weight.
Logarithmic transformed sFRP4 serum concentrations in GDM pregnancies were
2.04 ± 0.25 ng/ml and this was significantly higher than the control pregnancies (1.93 ± 0.28
ng/ml (p<0.05), Fig 1A). Additionally, Chemerin and Leptin were significantly increased in
GDM with 3.19 ± 0.13 ng/ml vs 3.15 ± 0.09 ng/ml for Chemerin (p<0.05, Fig 1B) and
1.44 ± 0.28 ng/ml vs 1.32 ± 0.24 ng/ml for Leptin (p<0.01, Fig 1C). On the contrary, Adipo-
nectin concentrations were significantly decreased in GDM with 2.83 ± 0.23 ng/ml vs
2.94 ± 0.20 ng/ml (p<0.01, Fig 1D).
Univariate logistic regression analysis of the logarithmic transformed data showed statisti-
cally significant odds ratios (OR) for all markers: 5.24 (95%CI 1.29–21.3) for sFRP4, 40.1 (95%
CI 1.53–1050) for Chemerin, 6.51 (95%CI 1.61–26.4) for Leptin and 0.09 (95%CI 0.02–0.49)
for Adiponectin (Table 2A). Therefore, all markers were subsequently included in a multivari-
ate logistic regression model (Table 2B). In this combined model, only Adiponectin showed a
statistically significant OR (0.12 (95%CI 0.02–0.68)).
The discriminative performance of the univariate models, expressed as AUC, were 0.581
(95%CI 0.474 to 0.687) for Chemerin, 0.601 (95%CI 0.503 to 0.700) for Leptin, 0.605 (95%CI
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0.505 to 0.704) for sFRP4 and 0.634 (95%CI 0.534 to 0.733) for Adiponectin. Discriminative
performance increased when all biomarkers were combined in a multivariate model (AUC
0.699 (95%CI 0.605 to 0.793, Fig 3).
Discussion
To the best of our knowledge, this is the first study reporting the association of increased
sFRP4 concentrations with the development of GDM in the first trimester. Additionally, we
show that combining sFRP4, Leptin, Chemerin and Adiponectin in a multivariate model gives
a good discrimination for GDM in the first trimester.
Increased concentrations of sFRP4 in first trimester samples of women who later developed
GDM could be explained by the fact that the sFRP4 gene was identified in a systems genetic
study as one of the genes associated with pancreatic islet dysfunction [57]. Furthermore, it was
reported that sFRP4 is overexpressed in pancreatic islet cells of patients with T2DM, while its
increased circulatory concentrations impair insulin secretion by β-cells and thereby reduce
glucose tolerance [51]. These findings point towards a direct role of sFRP4 in controlling the
insulin secretion from β-cells. In addition to its effect on glucose metabolism, elevated concen-
trations of sFRP4 also impair triglyceride metabolism in patients with T2DM [54]. Despite the
clear link between sFRP4 and T2DM, an association between sFRP4 and GDM has only been
Table 1. Baseline characteristics of pregnancies affected by gestational diabetes (GDM) and uncomplicated preg-
nancies (controls).
Variable GDM Controls p-value
(n = 50) (n = 100)
Maternal age (years) 35.0 34.8 0.678#
(31.8–37.3) (30.8–37.6)
Maternal weight (kg) 75 75 0.625#
(67–88) (64–85)
Maternal BMI (kg/m2) 26.6 26.2 0.802#
(22.6–30.1) (22.3–29.6)
Smoking 0 0 1.000##
(0%) (0%)
Parity 1 1 0.083#
(1–2) (0–2)
Gestational age at sample collection (days) 83 83 1.000#
(75–86) (75–86)
Gestational age at delivery (days) 281 281 0.417#
(273–284) (275–286)
Fetal gender (male) 27 55 0.908##
(54%) (55%)
Birth weight (g) 3718 3530 0.230#
(3310–3980) (3283–3875)
Birth weight percentile 65 49 0.180#
(37–79) (31–74)
Maternal age, weight, BMI and smoking were assessed at sample collection (first trimester of pregnancy). Data are
presented as median and interquartile range for continuous and N (%) for categorical variables.
# analysis by Mann-Witney U test and
## analysis by Chi-square test.
https://doi.org/10.1371/journal.pone.0242423.t001
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reported in the second trimester or later, and prior to this study not yet in the first trimester.
The phenotypic onset of GDM happens in the second trimester or later and, therefore, mea-
surement of markers in the second and third trimester shows more predictive power. How-
ever, sooner diagnosis is better, since a timely therapeutic intervention is essential to prevent
the adverse pregnancy outcome. Described higher concentrations of sFRP4 during GDM in
the second trimester support our suggested association in the first trimester. The biological
origin of a higher chance to develop GDM, when sFRP4 serum concentrations in the first tri-
mester are increased, is as yet unclear and remains to be investigated further. However,
Fig 1. Boxplots of uncomplicated (control) pregnancies or pregnancies that will develop gestational diabetes
(GDM). Median, 25%-75% percentiles (box) and 5%-95% percentiles (whiskers) of sFRP4 (A), Chemerin (B), Leptin,
(C) and Adiponectin (D) log10 transformed concentrations. � = p<0.05; �� = p<0.01.
https://doi.org/10.1371/journal.pone.0242423.g001
Table 2. Logarithmic transformed mean concentrations and standard deviation (SD) and logistic regression analysis of sFRP4, Chemerin, Leptin and Adiponectin
concentrations in gestational diabetes (GDM) and uncomplicated (control) pregnancies.
A. Univariate logistic regression analysis
Markers Mean concentration ±SD OR (95%CI) p-value
(ng/ml)
Control GDM
(n = 100) (n = 50)
sFRP4 1.93 ± 0.28 2.04 ± 0.25 5.24 (1.29–21.27) 0.020
Chemerin 3.15 ± 0.09 3.19 ± 0.13 40.10 (1.53–1049.6) 0.027
Leptin 1.32 ± 0.24 1.44 ± 0.28 6.51 (1.61–26.44) 0.009
Adiponectin 2.94 ± 0.20 2.83 ± 0.23 0.09 (0.02–0.49) 0.005
B. Multivariate logistic regression analysis
Markers OR (95%CI) p-value
sFRP4 2.15 (0.43–10.68) 0.350
Chemerin 12.83 (0.34–491.54) 0.170
Leptin 2.90 (0.59–14.14) 0.189
Adiponectin 0.12 (0.02–0.68) 0.017
Correlation between the markers within the control group were weak, but statistically significant for sFRP4 with Chemerin (R2 = 0.124, p<0.001), sFRP4 with Leptin (R2
= 0.145, p<0.001) and Chemerin with Leptin (R2 = 0.282, p<0.001). There was no statistically significant correlation between markers within the GDM group (Fig 2 and
Table 1A and 1B in S1 Table).
https://doi.org/10.1371/journal.pone.0242423.t002
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another member of the Wnt antagonists, sFRP5, has also been associated with GDM and
T2DM [58–60]. This link between GDM and two members of the sFRP protein family impli-
cates a role of the Wnt signaling pathway in impaired glucose tolerance. Furthermore, our
results are in concordance with previous studies that showed decreased Adiponectin concen-
trations [37,38,61] and increased Chemerin and Leptin concentrations [32,36,41,62] in the
first trimester of pregnancy in women who later developed GDM.
In contrast to T2DM, it is proposed that GDM has a hormonal and autoimmunological
background as underlying pathological mechanism [6–12]. This crosstalk scenario, fuelled by
Fig 3. Receiver-operating curve and logistic regression data for sFRP4, Chemerin, Leptin, Adiponectin and
multivariate model. AUC, area under the receiver-operating curve.
https://doi.org/10.1371/journal.pone.0242423.g003
Fig 2. Correlation plots of Adiponectin, Chemerin, Leptin and sFRP4 log10 transformed concentrations in GDM and control pregnancies.
https://doi.org/10.1371/journal.pone.0242423.g002
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adipokines, plays an important role in metabolic homeostasis under healthy conditions,
whereas a release of proinflammatory adipocytokines is important in the pathogenesis of
many metabolic disorders. Our panel of sFRP4, Adiponectin, Leptin and Chemerin confirms
this crosstalk scenario of GDM. This study was limited to four biomarkers and it is therefore
conceivable that parallel evaluation of more hormonal and inflammatory GDM-associated
markers, like sex hormone-binding globulin, C-reactive protein and/or sFRP5 [30,58,63,64],
would strengthen our initial observation and thereby validate the use of a panel, including
sFRP4, to predict the risk on GDM.
We have been able to select pregnancies with comparable and normal gestational age at
delivery, birth weight and limited adverse outcome. Although one might expect shorter pregnancy
durations and higher birth weights in GDM pregnancies, due to accurate screening and monitor-
ing of GDM pregnancies in the Netherlands, the number of adverse outcomes in these pregnan-
cies are relatively low [65,66]. Nevertheless, women who went through a GDM pregnancy are still
at considerably higher risk to develop T2DM later in life [67]. Since the cases and controls were
matched on potentially predictive variables such as BMI, it was not possible to evaluate the added
value of sFRP4 concentrations on top of these demographic baseline predictors.
The association of increased sFRP4 concentrations with the development of GDM was
observed in a cohort with a relatively low BMI (26.4 (± 5.2) kg/m2). The relatively low BMI
might indicate that our conclusions are drawn on pregnant women who are, based on current
prediction models, considered as low-risk GDM cases, since BMI is one of the major demo-
graphic baseline predictors [23]. Moreover, one of the major outcomes of GDM is an increased
fetal birth weight, but this was absent in our cohort [2,3]. Unfortunately, it is not possible to
say anything about the severity of the GDM cases or to conclude that only mild GDM cases
were included in this study, since the database did not have any information on (therapeutic)
interventions which might have influenced the fetal birth weight. Additionally, the absence of
more data of the individual women made it impossible to speculate what the actual cause of
GDM might have been. More significant observations might be obtained in an obese cohort
(BMI of�30 kg/m2), or GDM cases with an increased fetal birth weight/percentile.
This study also has some limitations. Firstly, the data were obtained from a relatively small
number of samples and it would be desirable to extend the observations of this study by using
a larger number of samples from an unselected and mixed population and preferably as a pro-
spective study. This will give the opportunity to critically validate the data of this discovery
study. Secondly, information on pregnancy outcome, including GDM, was collected through
self-reporting by the participating women. This may have led to classification bias, however,
previous studies based on this specific cohort have shown that self-reporting of pregnancy out-
comes shortly after pregnancy is a reliable method [68,69]. Thirdly, within the Dutch obstetric
care system it is standard policy to perform an OGTT only when indicated (e.g. based on risk
factors for GDM or excessive fetal growth observed on ultrasound). This might also have led
to classification bias of the diagnosis and thus a possible underestimation of GDM in the con-
trol group.
Nevertheless, we have shown in this study that an increased concentration of serum sFRP4
in the first trimester of pregnancy is associated with a higher risk to develop GDM later in
pregnancy and that including sFRP4 in a multi-marker model with Leptin, Chemerin and Adi-
ponectin gives a fair discrimination for GDM. Current prediction models in the first trimester
of pregnancy are mainly based on demographic parameters and their predictive power can be
improved when a biochemical marker is included. Validating sFRP4 in combination with
demographic parameters and the markers Adiponectin, Leptin and Chemerin in a prospective
cohort might increase the early prediction of GDM in the first trimester.
PLOS ONE First trimester adipokine levels and gestational diabetes
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